TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

Title
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 6_suppl, Pages 119-119
Publisher
American Society of Clinical Oncology (ASCO)
Online
2020-02-20
DOI
10.1200/jco.2020.38.6_suppl.119

Ask authors/readers for more resources

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now